ClinicalTrials.gg
Not yet recruitingNCT07377864NTM-LDUpdated Jan 30, 2026

Clinical Characteristics and Immune Escape Mechanism of Nontuberculous Mycobacterial Lung Disease in South China

An observational study in Nontuberculous Mycobacterial Lung Disease and Mycobacterium Avium Complex (MAC), sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Nontuberculous Mycobacterial lung disease (NTM-LD) is a significant infectious challenge. The precise causes remain unclear, diagnosis can be complex, treatment outcomes are often unsatisfactory, and the disease can severely affect a patient's quality of life. Environmental factors, such as the warm and humid climate in South China, may contribute to unique characteristics of NTM in this region, but systematic research is currently lacking.

This study aims to improve the understanding of NTM-LD in South China. It consists of two complementary parts:

  1. The first part is a retrospective review of medical records from approximately 1,500 NTM patients across multiple hospitals in South China. This analysis seeks to identify common patterns in symptoms, diagnostic findings, and treatment responses within this population.
  2. The second part is a prospective study involving about 106 current NTM-LD patients. Blood and lung fluid samples will be collected to analyze, using advanced laboratory techniques, how the patient's immune system responds to the infection. This investigation aims to uncover clues about why some cases are difficult to treat.

The overall goal of this research is to generate evidence that can aid healthcare providers in South China in diagnosing and managing NTM-LD more effectively. Please note that this is an observational study; no new drugs or experimental treatments are being tested.

Read the detailed description
  1. Background and Rationale NTM-LD presents significant clinical challenges due to its unclear pathogenesis, diagnostic complexity, suboptimal treatment outcomes, and poor prognosis. The unique climatic (hot, humid) and demographic factors in South China suggest potential regional variations in NTM epidemiology and clinical presentation. However, a systematic investigation into its clinical characteristics and underlying mechanisms in this region is lacking, impeding the development of localized precision medicine strategies.
  2. Study Objectives Primary Objective: To systematically characterize the epidemiological patterns, clinical phenotypes, and prognostic determinants of NTM-LD in the South China population.

    Secondary Objectives:

    To analyze the distribution of NTM species and their correlation with disease severity and radiological findings.

    To investigate host immune microenvironment alterations post-NTM infection, focusing on inflammatory responses and immune cell functional states.

    To explore molecular mechanisms associated with treatment refractoriness in NTM disease.

  3. Study Design

    This is a hybrid observational study comprising two distinct parts:

    • Part 1: A multicenter, retrospective, non-interventional survey study.
    • Part 2: A prospective observational study involving biospecimen collection and laboratory analysis.
  4. Study Populations and Sample Size

    • Part 1: Approximately 1,500 patients diagnosed with NTM lung disease per standard guidelines between January 2015 and May 2025 across multiple collaborating centers in South China.
    • Part 2: A subset of 106 consecutively enrolled, confirmed NTM patients from the collaborating network for prospective biospecimen collection.
  5. Methods and Procedures

    • Part 1 (Retrospective Survey): Data on demographics, clinical symptoms, imaging features (chest CT), microbiology, treatment regimens, and outcomes will be extracted from electronic health records. Statistical analyses will include descriptive summaries, correlation studies, and multivariable regression modeling to identify prognostic factors.
    • Part 2 (Prospective Study): Peripheral blood and bronchoalveolar lavage fluid (BALF) will be collected. Analyses will include:

    Molecular Biology: Real-time quantitative PCR for cytokine expression profiling; Western blot for protein-level assessment.

    Single-Cell Sequencing: To delineate immune cell composition, transcriptional states, and cell-cell interaction networks within the pulmonary immune microenvironment.

  6. Statistical Analysis For Part 1, appropriate statistical tests (e.g., Chi-square, t-test, ANOVA, Kaplan-Meier survival analysis, Cox regression) will be applied based on data types and distribution. For Part 2, bioinformatics pipelines specific for single-cell RNA sequencing data will be employed for clustering, differential expression, and pathway analysis. A p-value \<0.05 will be considered statistically significant.
  7. Ethics and Data Management The study protocol will be submitted for approval to The Eighth Affiliated Hospital of Sun Yat-Sen University Ethics Committee of all participating centers prior to initiation. Patient informed consent will be obtained for the prospective Part 2. All data will be de-identified, coded, and stored on secure, password-protected servers in compliance with data protection regulations.
  8. Significance This study is expected to generate a comprehensive clinical profile of NTM lung disease in South China and provide novel insights into its pathogenesis at the immune-microenvironment level. The findings may contribute to more accurate diagnostic criteria, prognostic models, and inform the future development of targeted therapeutic strategies for this refractory infection.
02

Conditions studied

  • Nontuberculous Mycobacterial Lung Disease
  • Mycobacterium Avium Complex (MAC)

Keywords

  • Nontuberculous Mycobacterial
  • South China
  • Immune Escape
  • Outcome
03

In context

Mycobacterium avium-intracellulare Infection

66 studies on the registry are indexed under Mycobacterium avium-intracellulare Infection; 8 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 50 across 11 observational studies indexed under Mycobacterium avium-intracellulare Infection.

Browse Mycobacterium avium-intracellulare Infection studies →

Lead sponsor

Eighth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study population comprises patients diagnosed with nontuberculous mycobacterial infection in South China. It includes two nested cohorts: (1) a large multicenter retrospective cohort of approximately 1,500 patients identified from hospital records between 2015 and 2025, from whom clinical and epidemiological data will be extracted; and (2) a prospective sub-cohort of about 106 patients consecutively enrolled from the aforementioned group, who will provide additional biospecimens (peripheral blood and bronchoalveolar lavage fluid) for mechanistic laboratory investigations.

Eligibility criteria

Inclusion Criteria:1. (Both Cohorts):

  • Patients diagnosed with nontuberculous mycobacterial according to standard guidelines.
  • Aged 18 years or older.
  • Available medical records covering the period from 2015 to 2025 (for the retrospective cohort).

    2. (Prospective Sub-cohort Additional):

  • Willing and able to provide written for biospecimen collection.
  • Clinically stable and suitable for undergoing research bronchoalveolar lavage (BAL) procedure, as judged by the investigator.

Exclusion Criteria: 1. (Both Cohorts):

  • Active tuberculosis or other dominant pulmonary infections.
  • Incomplete medical records that preclude adequate data extraction (for retrospective analysis).

    2. (Prospective Sub-cohort Additional):

  • to bronchoscopy or BAL procedure.
  • Pregnancy or lactation.
  • Any condition that, in the opinion of the investigator, would compromise patient safety or data integrity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective NTM Cohort

    This cohort consists of approximately 1,500 patients diagnosed with nontuberculous mycobacterial (NTM) across multiple hospitals in South China. Data, including demographics, clinical symptoms, imaging findings, microbiology results, and treatment outcomes, will be extracted retrospectively from electronic medical records for the period from January 2015 to May 2025.

    Other: Prospective Biospecimen Sub-cohort

Interventions

  • OtherProspective Biospecimen Sub-cohort

    Observational

06

What researchers measure

Primary outcomes

  1. Clinical Phenotype Distribution

    Proportion of patients with different clinical-radiological phenotypes of NTM-LD (nodular-bronchiectatic, fibrocavitary, hypersensitivity-like, and mixed patterns) based on chest CT imaging and clinical presentation.

    Time frame: At time of diagnosis (assessed retrospectively from medical records between January 2015 and May 2025)

  2. Treatment Response Categories

    Distribution of treatment outcomes including: (1) microbiological conversion (negative cultures for ≥12 months), (2) treatment failure (persistent positive cultures despite appropriate therapy), (3) treatment intolerance requiring discontinuation, and (4) spontaneous improvement without treatment.

    Time frame: 12 months post-diagnosis (assessed retrospectively from medical records between January 2015 and May 2025)

Secondary outcomes

  1. Spectrum of NTM Species

    The spectrum and relative frequency of nontuberculous mycobacteria (NTM) species isolated from respiratory specimens (including sputum and bronchoalveolar lavage fluid) will be determined through retrospective analysis of positive culture and species identification results from the hospital's microbiology laboratory database. All patients with confirmed NTM pulmonary disease will be included in this analysis.

    Time frame: Species distribution will be assessed at baseline, defined as the date of the first positive NTM culture from a respiratory specimen. Retrospective data collection will cover the period from January 2015 to May 2025.

  2. Clinical Prognostic Factors

    Specific clinical variables assessed for their association with treatment outcome. These include: presence of cavitation on baseline chest CT, body mass index (BMI) \< 18.5 kg/m² at diagnosis, CCI, NLR, NMLR, and a history of previous NTM treatment failure.

    Time frame: Assessed at baseline (within 7 days of enrollment).

  3. Immunological Prognostic Factors

    Specific immunological variables assessed for their association with treatment outcome. This primarily refers to the presence and titer of neutralizing anti-interferon-gamma autoantibodies (nIFN-γ-autoAbs) in serum.

    Time frame: Serum sample collected at baseline (within 7 days of enrollment) for antibody testing.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pan M, Wei Y, Luo C, Lin H, Lu W, Lin Y, Mai Z, Deng J, Huang Y, Yu H, Huang J, Zhang J. Tracheobronchial invasion by nontuberculous mycobacteria: a rare but overlooked clinical manifestation-a multicenter retrospective analysis. Front Cell Infect Microbiol. 2026 Jul 13;16:1872833. doi: 10.3389/fcimb.2026.1872833. eCollection 2026. PubMed 42516434 ↗

Individual participant data

Plan to share: Yes — What data in particular will be shared? De-identified individual participant data that underlie the results reported in the primary publication (including baseline characteristics, primary and secondary outcome measures). What other documents will be available? Study protocol, statistical analysis plan, and informed consent form (if applicable). When will data be available (start and end dates)? • Beginning 1year after the publication of the primary results and ending 5 years thereafter. With whom? • Researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. For what types of analyses? For individual participant data meta-analysis or other secondary analyses approved by the proposal assessment committee. By what mechanism will data be made available? Proposals should be directed to [principal investigator's email address, jqzhang2002@126.com]. To gain access, requestors will need to sign a data access agreement. Data will be shared v

Supporting information: Study protocol

Time frame: Beginning 1year after the publication of the primary results and ending 5 years thereafter.

Access criteria: Access will be granted to external researchers (including individuals affiliated with academic institutions, healthcare organizations, or non-commercial research entities) who provide a methodologically sound research proposal that has received ethical approval (if applicable) from an institutional review board. The proposal must align with the original study's ethical framework and informed consent provisions. Proposals for commercial purposes will not be considered. Requestors may access the following de-identified datasets and documents: 1. Individual Participant Data: Key de-identified variables including demographics (age, gender), clinical characteristics (symptoms, imaging phenotypes, NTM species), laboratory results, and primary/secondary outcome measures. 2. Supporting Documents: The final approved study protocol, the statistical analysis plan, the informed consent form template, and the data dictionary defining all variables.

Data sharing details ↗ · www.icmje.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jun 2028, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Jan 30, 2026
StartEst.
Jan 1, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377864
Lead sponsor
Eighth Affiliated Hospital, Sun Yat-sen University
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Jianquan Zhang, Dr
Contact
jqzhang2002@126.com
0755-83982222
Mianluan Dr Pan, Dr
Contact
2693754132@qq.com
Jianquan Zhang
study chair · The Eighth Affiliated Hospital of Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion